


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo

英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

**VOLUNTARY ANNOUNCEMENT
POSSIBLE PARTICIPATION IN THE ESTABLISHMENT OF AN
INVESTMENT FUND**

This announcement is made by InSilico Medicine Cayman TopCo (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform its shareholders and potential investors of the latest business development of the Group.

The Company is considering participating in the proposed establishment of an investment fund, tentatively named Insilico Pudong Development Value Partners (Shanghai) Private Equity Investment Fund Partnership (Limited Partnership)* (英矽浦發惠理(上海)私募股權投資基金合夥企業(有限合夥)). (the “**Insilico Medicine Exponential Technology Fund**” or “**Fund**”) through a series of transactions (the “**Possible Transactions**”).

As part of the implementation structure, the Company proposes to contribute RMB3 million through its wholly-owned subsidiary, Insilico Medicine (Shanghai) Investment Co., Ltd.* (英矽智能(上海)投資有限公司) (“**Insilico Shanghai Investment**”) to establish a joint venture (the “**Joint Venture**”) with Shanghai Pudong Construction Co., Ltd. (上海浦東建設股份有限公司) (“**Pudong Construction**”, a company listed on the Shanghai Stock Exchange with stock code 600284) and Shanghai Pudong Development (Group) Co., Ltd.* (上海浦東發展(集團)有限公司, the controlling shareholder of Pudong Construction). The capital contribution by Insilico Shanghai Investment is expected to represent 60% of the registered capital of the Joint Venture, being RMB5 million. Upon completion of its establishment, the Joint Venture is expected to become an indirect non-wholly owned subsidiary of the Company, and its financial results are expected to be consolidated into the accounts of the Group.

Following the establishment of the Joint Venture, the Company proposes to contribute a total of RMB302.5 million through its wholly-owned subsidiary, Insilico Medicine Ltd.* (英矽智能科技(上海)有限公司) and the Joint Venture to establish the Fund with Value Partners Equity Investment Management (Shenzhen) Co., Ltd.* (惠理股權投資管理(深圳)有限公司, a wholly-owned subsidiary of Value Partners Group Limited (a company listed on the Stock Exchange with stock code 806)), Pudong Construction and other prospective investors.

The Fund is proposed to be established as a limited partnership in the PRC under the proposed name of Insilico Pudong Development Value Partners (Shanghai) Private Equity Investment Fund Partnership (Limited Partnership)* (英矽浦發惠理(上海)私募股權投資基金合夥企業(有限合夥)). The Fund is expected to principally focus on investments in the biopharmaceutical sector and other related industries. The target fund size is expected to be RMB1.01 billion.

The board of directors of the Company (the “**Board**”) believes that the Possible Transactions are aligned with the Group’s strategic direction, and would enable the Group to participate in growth opportunities arising from the continued development and innovation of the biopharmaceutical and life sciences sectors.

As at the date of this announcement, no definitive agreement has been entered in respect of the Possible Transactions. The implementation of the Possible Transactions, including any capital contribution and deployment, remains subject to the execution of definitive agreements and the phased capital contribution arrangements to be agreed therein. As such, the Possible Transactions may or may not proceed. If the Company enters into the definitive agreements relating to the Possible Transactions, it is expected to constitute a discloseable transaction of the Company under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”). The Company will make further announcement(s) in relation to the Possible Transactions as and when appropriate in accordance with the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, August 18, 2026

As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Chuen Yan Leung, Ph.D. as non-executive director; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.

* *For identification purpose only.*